|Bid||2.3200 x 3200|
|Ask||2.3700 x 1400|
|Day's range||2.2500 - 2.3900|
|52-week range||1.4800 - 5.9800|
|Beta (5Y monthly)||1.91|
|PE ratio (TTM)||N/A|
|Earnings date||08 Nov 2021 - 12 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||9.29|
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Investors need to pay close attention to Infinity (INFI) stock based on the movements in the options market lately.
CAMBRIDGE, Mass., November 22, 2021--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, today announced that Adelene Perkins, Chief Executive Officer, will present at the upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference.